netFormulary
 Report : Medicines with links to NICE 26/10/2020 12:49:52

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abciximab 02.09 Formulary NICE TA47: Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of ACS
Abemaciclib 08.01.05 Formulary NICE TA563: abemaciclib for previously untreated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab/ adalimumab biosimilar 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab/ adalimumab biosimilar 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab/ adalimumab biosimilar 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab/ adalimumab biosimilar 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab/ adalimumab biosimilar 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab/ adalimumab biosimilar 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab/ adalimumab biosimilar 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for plaque psoriasis in children and young people
Adalimumab/ adalimumab biosimilar 13.05.03 Formulary NICE TA146: Adalimumab for adults with psoriasis
Adalimumab/ adalimumab biosimilar 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab/ adalimumab biosimilar 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab/ adalimumab biosimilar 11.04 Formulary NICE TA460: Non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Adrenaline / epinephrine 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA294: Wet age-related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA346: Diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA409: Visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA305: Visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA486:Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Formulary TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.04 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alendronic acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177 - Alitretinoin for severe chronic hand eczema
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Alteplase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Anastrozole 08.03.04.01 Formulary NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Routine antenatal anti-D prophylaxis for women who are rhesus D negative
Apixaban 02.08.02 Formulary NICE TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular AF
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of VTE after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for moderate to severe plaque psoriasis
Apremilast 10.01.03 Formulary NICE TA455: Apremilast for active psoriatic arthritis
Apremilast 13.05.03 Non Formulary NICE TA372: Apremilast for psoriatic arthritis
Apremilast 13.05.03 Non Formulary NICE TA433 : Apremilast for treating active psoriatic arthritis
Apremilast 13.05.03 Non Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Ataluren 10.02 Formulary NICE HST3: Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atezolizumab 08.01.05 Formulary NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer
Atezolizumab 08.01.05 Formulary NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Atezolizumab 08.01.05 Formulary NICE TA 520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA 492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Avatrombopag 09.01.04 Formulary NICE TA626:Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Avelumab 08.01.05 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 08.01.05 Formulary NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Formulary NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Basiliximab 08.02 Formulary NICE TA482:Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Non Formulary NICE TA99: Immunosuppressives in renal transplant (Children)
Basiliximab 08.02.02 Non Formulary NICE TA85: Immunosuppressives in renal transplant (Adults)
Bee/Wasp venom allergen extracts 03.04.02 Formulary NICE TA246: Pharmalgen for bee and wasp venom allergy
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Benralizumab 03.04.02 Formulary NICE TA565: Benralizumab for treating severe eosinophilic asthma
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.01.05 Formulary NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.01.05 Formulary NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Non Formulary NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum neurotoxin type A 01.02 Formulary NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea.
Botulinum Toxin Type A 04.07.04.02 Formulary NICE TA260: Botulinum toxin type A for the prevention of headaches in adults with chronic migraine
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA446 : Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05.03 Formulary NICE TA511:Brodalumab for treating moderate to severe plaque psoriasis
Buprenorphine 04.10.03 Formulary NICE TA114: Methadone and buprenorphine for the management of opioid dependence
Buprenorphine 04.10.03 Formulary NICE TA114: Methadone and buprenorphine for the management of opioid dependence
Burosumab 09.08.01 Formulary NICE Highly Specialised Technology Guidance (HST8): Burosumab for treating X-linked hypophosphataemia in children and young people
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516:Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Cannabidiol 04.08.01 Formulary NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol 04.08.01 Formulary NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Cannabidiol 04.08.01 Formulary NICE NG144: Cannabis-based medicinal products
Cannabis extract 10.02.02 Formulary NICE Guidelines NG144 Cannabis-based medicinal products Nov 2019
Capecitabine 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine 08.01.03 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer
Capecitabine 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Carfilzomib 08.01.05 Formulary NICE TA457 : Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Cemiplimab 08.02.04 Formulary NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol 13.05.03 Formulary NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Formulary NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Cetuximab 08.01.05 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 0.1% 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cilostazol 02.06.04 Non Formulary NICE TA223:Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Cinacalcet 09.05.01.02 Formulary NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cladribine 10.02 Formulary NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate 05.01.07 Formulary NICE TA 276 - Dry powder inhalers for pseudomonas lung infection in cystic fibrosis
Collagenase 10.03.01 Formulary NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for the prevention of stroke and systemic embolism in AF
Dabigatran 02.08.02 Formulary NICE TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran for the prevention of VTE after hip or knee replacement surgery in adults
Dabrafenib 08.01.05 Formulary NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Formulary NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
Dacomitinib 08.01.05 Formulary NICE TA595 Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 08.01.05 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Formulary NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin Alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Darbepoetin Alfa 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265:Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA204: Denosumab for the prevention of osteoporotic fractures in postmenopausal women
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA460: Non-infectious uveitis
Dimethyl fumarate 13.05.02 Formulary NICE TA475: Dimethyl fumarate for moderate to severe plaque psoriasis
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dinutuximab beta 08.01.05 Formulary NICE TA538: Dinutuximab beta for treating neuroblastoma
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Dipyridamole 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
Docetaxel 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Donepezil 04.11 Formulary NICE TA217: Alzheimers disease donepezil, galantamine, rivastigmine and memantine
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxylamine and pyridoxine 04.06 Non Formulary NICE Evidence Summary Doxylamine/pyridoxine (Xonvea) for treating nausea and vomiting of pregnancy June 2019
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01.05 Formulary NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
Eculizumab 09.01.03 Formulary NICE HST1:Eculizumab for treating atypical haemolytic uraemic syndrome
Eculizumab 09.01.03 Formulary NICE TA647: Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal)
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke and systemic embolism in people with non‑valvular AF
Edoxaban 02.08.02 Formulary NICE TA354: Edoxaban for treating and preventing DVT and PE
Elbasvir with grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura
Eluxadoline 01.04.02 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA562: with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Formulary NICE TA153: Entecavir for the treatment of chronic hepatitis B
Entrectinib 08.01.05 Formulary NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Entrectinib 08.01.05 Formulary NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Epoetin alfa 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Epoetin beta 09.01.03 Formulary NICE NG8: Chronic kidney disease: managing anaemia
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 13.05.03 Formulary NICE TA103: Etanercept and efalizumab for adults with psoriasis
Etanercept 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for plaque psoriasis in children and young people
Etanercept/etanercept biosimilar 13.05.03 Formulary NICE TA455: Adalimumab, etanercept and ustekinumab for plaque psoriasis in children and young people
Etanercept/etanercept biosimilar 13.05.03 Formulary NICE TA103: Efalizumab and etanercept for adults with psoriasis
Etanercept/etanercept biosimilar 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept/etanercept biosimilar 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept/etanercept biosimilar 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept/etanercept biosimilar 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept/etanercept biosimilar 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etelcalcetide 09.05.01.02 Formulary NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.02.02 Non Formulary NICE TA348: Everolimus for preventing organ rejection in liver transplantation
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Everolimus 08.01.05 Formulary NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Formulary NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms in men: management
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Fludarabine monotherapy for the first-line treatment of chronic lymphocytic leukaemia
Flunarizine 04.07.04.02 Non Formulary NICE ESUOM33: Migraine prophylaxis: flunarizine Sept 2014
Fluocinolone acetonide 11.04.01 Formulary NICE TA301: Chronic diabetic macular oedema
Fluocinolone acetonide 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fremanezumab 04.07.04.02 Formulary NICE TA631: Fremanezumab for preventing migraine
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Galantamine 04.11 Formulary NICE TA217: Alzheimers disease donepezil, galantamine, rivastigmine and memantine
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gefitinib 08.01.05 Formulary NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Gemcitabine 08.01.03 Formulary NICE TA25: Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin 08.01.05 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Gilteritinib 08.01.05 Formulary NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia
Glasdegib 08.01.05 Non Formulary NICE TA646: Glasdegib with chemotherapy for untreated acute myeloid leukaemia (terminated appraisal)
Glatiramer acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glatiramer acetate 08.02.04 Formulary NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
Glecaprevir with pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220: Golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis
Ibandronic acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Formulary NICE TA491:Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Formulary NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib 08.01.05 Formulary NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA209:Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohns disease
Infliximab 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for adults with psoriasis
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: Psoritic arthritis
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab biosimilar 01.05.03 Formulary NICE TA163: Infliximab for acute exacerbations of ulcerative colitis
Infliximab biosimilar 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohns disease
Infliximab biosimilar 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab biosimilar 10.01.03 Non Formulary NICE ES29: Remsima (infliximab biosimilar) for subcutaneous injection for managing rheumatoid arthritis
Infliximab/infliximab biosimilar 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab/infliximab biosimilar 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab/infliximab biosimilar 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab/infliximab biosimilar 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab/infliximab biosimilar 13.05.03 Formulary NICE TA134: Infliximab for adults with psoriasis
Inositol nicotinate 02.06.04 Non Formulary NICE TA223:Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Inotersen 09.08.01 Formulary NICE Highly Specialised Technology Guidance (HST9): Inotersen for treating hereditary transthyretin amyloidosis
Inotuzumab ozogamicin 08.01.05 Formulary NICE TA 541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Interferon Beta 08.02.04 Non Formulary NICE TA32: Interferon Beta for MS
Interferon Beta 08.02.04 Formulary NICE TA32: Beta interferon and glatiramer acetate for the treatment of multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ivabradine 02.06.03 Formulary NICE TA267: Ivabradine for treating chronic heart failure
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Formulary NICE TA442 : Ixekizumab for moderate to severe plaque psoriasis
Ixekizumab 10.01.03 Formulary TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lanadelumab 300mg 03.04.03 Formulary NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Larotrectinib 08.01.05 Formulary NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours
Ledipasvir with sofosbuvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenalidomide 08.02.04 Formulary NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma
Lenvatinib 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Letermovir 05.03.02.02 Formulary NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant
Letrozole 08.03.04.01 Formulary NICE TA112: Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Liposomal daunorubicin-cytarabine 08.01.05 Formulary NICE TA552: Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia
Lorlatinib 08.01.05 Formulary NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lusutrombopag 09.01.04 Formulary NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Lutetium (177Lu) oxodotreotride 08.01.05 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation 03.07 Formulary NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
Memantine 04.11 Formulary NICE TA217: Alzheimers disease donepezil, galantamine, rivastigmine and memantine
Mepolizumab 03.04.02 Formulary NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma
Methadone 1mg/ml 04.10.03 Formulary NICE TA114: Methadone and buprenorphine for the management of opioid dependence
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Formulary NICE TA235: Mifamurtide for the treatment of osteosarcoma
Minocycline 05.01.03 Non Formulary NICE: Minocycline safety concerns
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for treating symptoms of overactive bladder
Mycophenolate mofetil 08.02.01 Formulary NICE TA482:Immunosuppressive therapy for kidney transplant in children and young people
Mycophenolate mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Mycophenolate mofetil 08.02.01 Formulary NICE TA482:Immunosuppressive therapy for kidney transplant in children and young people
Mycophenolate mofetil 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Peripheral arterial disease: diagnosis and management
Naldemedine 01.06.06 Formulary NICE TA651: Naldemedine for treating opioid-induced constipation
Nalmefene 04.10.01 Formulary NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Naltrexone for the management of opioid dependence
Natalizumab 08.02.04 Formulary NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Neratinib 08.01.05 Formulary NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nintedanib 03.11 Non Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Niraparib 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.01.05 Formulary NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Formulary NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.01.05 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA530:Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.01.05 Formulary NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease
Nivolumab 08.01.05 Formulary NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nusinersen 10.02 Formulary NICE TA588: Nusinersen for treating spinal muscular atrophy
Obeticholic acid 01.09.01 Formulary NICE TA443 : Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab
Ocrelizumab 08.02.04 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.04 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 11.08.02 Formulary NICE TA297: Vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.01.05 Formulary NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a BRCA1 or BRCA2 mutation.
Olaparib 08.01.05 Formulary NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Formulary NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Oseltamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Oseltamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Osimertinib 08.01.05 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes C) colon cancer
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389:Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel - Albumin Bound 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.01.05 Formulary NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Panitumumab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer sorbitex calcium 09.02.01.01 Formulary NICE TA623 Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib intravitreal inj 11.08.02 Non Formulary NICE TA155: Age-related macular degeneration
Pegaspargase 08.01.05 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon alfa-2a 05.03.03 Formulary NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon alfa-2a 05.03.03 Formulary NICE TA300: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2a 05.03.03 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2a 05.03.03 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon alfa-2a 05.03.03 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA96: Adefovir dipivoxil and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA300: Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people
Peginterferon Alfa-2b 05.03.03 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 05.03.03 Formulary NICE TA300: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 05.03.03 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 08.02.04 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa-2b 08.02.04 Formulary NICE TA300: Interferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon Beta-1a 08.02.04 Formulary NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA519:Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence
Pembrolizumab 08.01.05 Formulary NICE TA557: Pembrolizumab for untreated, metastatic, non-squamous non-small-cell lung cancer, with pemetrexed and platinum chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA190: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pentosan polysulfate sodium 07.04.03 Formulary NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome
Pentoxifylline 02.06.04 Non Formulary NICE TA223:Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Peristeen® anal irrigation system 01.06.05 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Pirfenidone 03.11 Formulary NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkins B‑cell lymphoma
Polatuzumab vedotin 08.01.05 Formulary Polatuzumab vedotin (Polivy) with rituximab and bendamustine for treating relapsed or refractory diffuse large B cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317: Prasugrel with PCI for treating ACS
Prucalopride 01.06.07 Formulary NICE TA211: Prucalopride for the treatment of chronic constipation in women
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA160: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab 11.08.02 Formulary NICE TA155: Age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA274: Diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA283: Visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA298: Choroidal neovascularisation associated with pathological myopia
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Remdesivir 05.03 Formulary NICE ES27: Remdesivir for treating hospitalised patients with suspected or confirmed COVID-19 Jun 2020
Reslizumab 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophillic asthma
Reteplase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA300: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribociclib 08.01.05 Formulary NICE TA 496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.01.05 Formulary NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin 05.01.07 Formulary NICE TA 337 - Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab/ rituximab biosimilar 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab/rituximab biosimilar 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab/rituximab biosimilar 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban 02.08.02 Formulary NICE TA170: Rivaroxaban for the prevention of VTE after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE
Rivaroxaban 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent VTE
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with AF
Rivaroxaban 02.08.02 Formulary NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of ACS
Rivastigmine 04.11 Formulary NICE TA217: Alzheimers disease donepezil, galantamine, rivastigmine and memantine
Roflumilast 03.03.03 Formulary NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura
Rucaparib 08.01.05 Formulary NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Formulary NICE TA350: Secukinumab for moderate to severe plaque psoriasis
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir with velpatasvir 05.03.03.02 Formulary NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir/velpatasvir/voxilaprevir 05.03.03.02 Formulary NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Human growth hormone (somatropin) in adults with growth hormone deficiency
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Stiripentol 04.08.01 Formulary NICE CG137: Epilepsies: diagnosis and management Jan 2012
Streptokinase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Sunitinib 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir for the treatment of genotype 1 chronic hepatitis C
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Temsirolimus 08.01.05 Non Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Tenecteplase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Tenofovir disoproxil fumarate 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide 06.06.01 Formulary NICE TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Thiamine (vitamin B1) 09.06.02 Formulary NICE CG100: Alcohol-use disorders: diagnosis and management of physical complications
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Formulary NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tivozanib 08.01.05 Formulary NICE TA512:Tivozanib for treating advanced renal cell carcinoma
Tobramycin 05.01.04 Formulary NICE TA 276 - Dry powder inhalers for pseudomonas lung infection in cystic fibrosis
Tobramycin inhaler 05.01.04 Non Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA518:Tocilizumab for treating giant cell arteritis
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA247: Tocilizumab for the treatment of rheumatoid arthritis
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tofacitinib 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Trabectedin 08.01.05 Formulary NICE TA185:Trabectedin for the treatment of advanced soft tissue sarcoma
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544:Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE TA257: Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
Trastuzumab 08.01.05 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trastuzumab 08.01.05 Formulary NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab emtansine 08.01.05 Formulary NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab emtansine 08.01.05 Formulary NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
Treosulfan 08.01.01 Formulary NICE TA640: Treosulfan with fludarabine for malignant disease before allogenic stem cell transplant
Trifluridine and tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 01.05.03 Formulary NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis
Ustekinumab 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 13.05.03 Formulary NICE TA180: Ustekinumab for moderate to severe psoriasis
Ustekinumab 13.05.03 Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for plaque psoriasis in children and young people
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin 11.08.02 Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vitamins B and C 09.06.02 Formulary NICE CG100: Alcohol-use disorders: diagnosis and management of physical complications
Vitamins B and C 09.06.02 Formulary NICE CG115: Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and alcohol dependence
Vortioxetine 04.03.04 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Zaleplon 04.01.01 Non Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zanamivir 05.03.04 Formulary NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza
Zanamivir 05.03.04 Formulary NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza
Zoledronic acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Non Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia
Southampton Joint Formulary